The estimated Net Worth of James R Iii Gavin is at least $2.47 Million dollars as of 3 August 2020. James Gavin owns over 14,899 units of Baxter International stock worth over $2,136,563 and over the last 22 years he sold BAX stock worth over $0. In addition, he makes $336,652 as Independent Director at Baxter International.
Sign up
James Gavin BAX stock SEC Form 4 insiders trading
James has made over 9 trades of the Baxter International stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 14,899 units of BAX stock worth $568,248 on 3 August 2020.
The largest trade he's ever made was exercising 18,750 units of Baxter International stock on 28 March 2018 worth over $539,813. On average, James trades about 982 units every 36 days since 2003. As of 3 August 2020 he still owns at least 54,407 units of Baxter International stock.
You can see the complete history of James Gavin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Gavin biography
Dr. James R. Gavin, III M.D. Ph.D. is an Independent Director of the Company. Dr. Gavin is the Chief Medical Officer of Healing Our Village, Inc., a healthcare corporation that specializes in targeted advocacy, training, education, disease management and outreach for healthcare professionals and minority communities, having previously served as Chief Executive Officer and Chief Medical Officer from 2007 until November 2019, and Executive Vice President for Clinical Affairs from 2005 to 2007. Dr. Gavin is also Clinical Professor of Medicine and Senior Advisor of Health Affairs at Emory University, a position he has held since 2005, and Clinical Professor of Medicine at Indiana University School of Medicine in Indianapolis, a position he has held since 2008. From 2002 to 2005, Dr. Gavin was President of the Morehouse School of Medicine and from 1991 to 2002 he served as Senior Science Officer at Howard Hughes Medical Institute, a non-profit medical research organization. He previously served as a director of Amylin Pharmaceuticals, Inc. and Baxalta, before it was acquired by Shire in June 2016 and before Shire was acquired by Takeda Pharmaceutical Company in 2019.
What is the salary of James Gavin?
As the Independent Director of Baxter International, the total compensation of James Gavin at Baxter International is $336,652. There are 14 executives at Baxter International getting paid more, with Jose Almeida having the highest compensation of $13,913,800.
How old is James Gavin?
James Gavin is 74, he's been the Independent Director of Baxter International since 2003. There are no older and 28 younger executives at Baxter International.
What's James Gavin's mailing address?
James's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Insiders trading at Baxter International
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, and Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
What does Baxter International do?
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
What does Baxter International's logo look like?
Complete history of James Gavin stock trades at Baxter International
Baxter International executives and stock owners
Baxter International executives and other stock owners filed with the SEC include:
-
Jose Almeida,
Chairman of the Board, President, Chief Executive Officer -
James Saccaro,
Chief Financial Officer, Executive Vice President -
Jeanne Mason,
Senior Vice President - Human Resources -
Giuseppe Accogli,
Senior Vice President, President- America -
Sean Martin,
Senior Vice President, General Counsel -
Cristiano Franzi,
Senior Vice President and President, EMEA -
Jose E. Almeida,
Chairman, Pres & CEO -
Cristiano Franzi,
Sr. VP & Pres for EMEA -
Giuseppe Accogli,
Exec. VP & COO -
James K. Saccaro,
Exec. VP & CFO -
Sean B. W. Martin,
Sr. VP & Gen. Counsel -
Thomas Stallkamp,
Lead Independent Director -
Albert Stroucken,
Independent Director -
Peter Hellman,
Independent Director -
James Gavin,
Independent Director -
Patricia Morrison,
Independent Director -
Stephen Oesterle,
Independent Director -
Amy Wendell,
Independent Director -
John Forsyth,
Independent Director -
Michael Mahoney,
Independent Director -
Cathy Smith,
Independent Director -
Thomas Chen,
Independent Director -
Jacqueline Kunzler,
Senior Vice President and Chief Quality Officer -
Andrew Frye,
Senior Vice President and President, APAC -
Brian Stevens,
Senior Vice President, Chief Accounting Officer, Controller -
David S. Rosenbloom,
Sr. VP & Gen. Counsel -
Clare Trachtman,
VP of Investor Relations -
Brian C. Stevens,
Sr. VP, Chief Accounting Officer & Controller -
Wilber C. Boren IV,
Pres of Advanced Surgery -
Andrew Frye,
Sr. VP & Pres of APAC -
Jeanne K. Mason,
Sr. VP of HR -
Stacey Eisen,
Sr. VP of Global Communications -
Talvis P. Love,
Sr. VP & Chief Information Officer -
David P. Scharf,
Corporate Vice President -
Kees J Storm,
Director -
Marcus Schabacker,
CVP, Chief Scientific Officer -
Robert Felicelli,
CVP, Quality -
Brik V Eyre,
CVP, Hospital Products -
Carole J Uhrich,
Director -
Paul Vibert,
CVP, International -
Scott Pleau,
CVP - Operations -
Caroline Karp,
CVP, Controller -
Point Llc Loeb Daniel S Third,
-
Christopher A. Toth,
EVP,Group Pres, Kidney Care -
William A. Ii Ampofo,
Director -
Steven Flynn,
SVP, President, APAC -
Peter M Wilver,
Director -
David Brent Shafer,
Director -
Thomas J Jr Sabatino,
Senior Vice President -
Yuan Chia Pei,
Director -
Cheryl L White,
Corporate Vice President -
Joy A Amundson,
Corporate Vice President -
Jill M Schaaf,
CVP, Renal -
Harry M Jansen Jr Kraemer,
Chairman and -
Robert J. Hombach,
Corporate Vice President & CFO -
James E Utts,
Corporate Vice President -
Uma Chowdhry,
Director -
Peter J Arduini,
Corporate Vice President -
Bruce Mc Gillivray,
Corporate Vice President -
Sebastian J Bufalino,
Corporate Vice President -
Jean Luc Butel,
Corporate Vice President -
James M Gatling,
Corporate Vice President -
John C Moon,
Corporate Vice President -
Salto Carlos Del,
Senior Vice President -
Wayne T Hockmeyer,
Director -
Joseph B Martin,
Director -
Michael J Baughman,
Corporate Vice President -
Steven J Meyer,
Treasurer -
Michael J Tucker,
Senior Vice President -
James R Hurley,
Corporate Vice President -
Monroe E Trout,
Director -
Thomas Fang Tyan Chen,
Director -
Nevelle J Jeharajah,
Corporate Vice President -
Robert M Davis,
Corp. VP, CFO and Treasurer -
Jan Stern Reed,
Corporate Secretary -
Thomas H Glanzmann,
Senior Vice President -
Walter E Boomer,
Director -
Gail D Fosler,
Director -
Phillip L. Batchelor,
Corporate Vice President -
Karenann K Terrell,
Corporate Vice President -
Robert L Jr Parkinson,
Chairman of the Board and -
Karen J May,
Corporate Vice President -
Timothy P Lawrence,
CVP, Operations -
Blake E Devitt,
Director -
John J Greisch,
Senior Vice President & CFO -
Munib Islam,
Director -
Gregory P Young,
Corporate Vice President -
Susan R Lichtenstein,
Corporate Vice President, -
Lawrence T Gibbons,
Corporate Vice President -
David F Drohan,
Senior Vice President -
Fred L Turner,
Director -
Norbert G Riedel,
Corporate Vice President -
Brian P Anderson,
Senior Vice President -
Ludwig Hantson,
Corporate Vice President -
David S. Wilkes,
Director -
Nancy M Schlichting,
Director -
Joel T. Grade,
EVP and CFO -
Alok Sonig,
EVP,Group President, Pharma -
David S. Rosenbloom,
EVP and General Counsel -
Heather Knight,
EVP,Group Pres,Med Products -
Reazur Rasul,
EVP,Group Pres, Healthcare -
Jeffrey A Craig,
Director -
Stephen H Rusckowski,
Director -
James W Borzi,
EVP,Chief Supply Chain Officer